IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
86 Drug Developers Raised $17bn, Generated 86% Average Return
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
You may also be interested in...
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.
The company will seek emergency use authorization to prevent outbreaks in nursing homes. Regeneron is also positioning its antibody cocktail to prevent infections.